The spliceosome accurately promotes precursor messenger-RNA splicing by recognizing specific noncoding intronic tracts including the branch point sequence (BPS) and the 3'-splice-site (3'SS). Mutations of Hsh155 (yeast)/SF3B1 (human), which is a protein of the SF3b factor involved in BPS recognition and induces altered BPS binding and 3'SS selection, lead to mis-spliced mRNA transcripts. Although these mutations recur in hematologic malignancies, the mechanism by which they change gene expression remains unclear. In this study, multi-microsecond-long molecular-dynamics simulations of eighth distinct ∼700,000 atom models of the spliceosome Bact complex, and gene sequencing of SF3B1, disclose that these carcinogenic isoforms destabilize intron binding and/or affect the functional dynamics of Hsh155/SF3B1 only when binding non-consensus BPSs, as opposed to the non-pathogenic variants newly annotated here. This pinpoints a cross-talk between the distal Hsh155 mutation and BPS recognition sites. Our outcomes unprecedentedly contribute to elucidating the principles of pre-mRNA recognition, which provides critical insights on the mechanism underlying constitutive/alternative/aberrant splicing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843770PMC
http://dx.doi.org/10.3390/biom9100633DOI Listing

Publication Analysis

Top Keywords

pre-mrna recognition
8
bps recognition
8
disclosing impact
4
impact carcinogenic
4
carcinogenic sf3b
4
sf3b mutations
4
mutations pre-mrna
4
recognition
4
recognition all-atom
4
all-atom simulations
4

Similar Publications

Highly recurrent somatic mutations in the gene encoding the core splicing factor SF3B1 are drivers of multiple cancer types. SF3B1 is a scaffold protein that orchestrates multivalent protein-protein interactions within the spliceosome that are essential for recognizing the branchsite (BS) and selecting the 3' splice site during the earliest stage of pre-mRNA splicing. In this review, we first describe the molecular mechanism by which multiple oncogenic SF3B1 mutations disrupt splicing.

View Article and Find Full Text PDF
Article Synopsis
  • Eukaryotic tRNA precursors need to be processed sequentially to become mature tRNAs, with ELAC2 being essential for processing both nucleus-encoded (nu-tRNAs) and mitochondria-encoded (mt-tRNAs) types.
  • ELAC2 can independently process nu-tRNAs, but for most mt-tRNAs, it requires the assistance of TRMT10C and SDR5C1, especially for those without a canonical structure.
  • The study reveals that while standard tRNAs are recognized through direct interactions between ELAC2 and the RNA, the processing of noncanonical mt-tRNAs relies on interactions between ELAC2 and the proteins TRMT10C and SDR5C1, highlighting an evolved mechanism for tRNA maturation in
View Article and Find Full Text PDF

Plant immunity involves a complex and finely tuned response to a wide variety of pathogens. Alternative splicing, a post-transcriptional mechanism that generates multiple transcripts from a single gene, enhances both the versatility and effectiveness of the plant immune system. Pathogen infection induces alternative splicing in numerous plant genes involved in the two primary layers of pathogen recognition: pattern-triggered immunity (PTI) and effector-triggered immunity (ETI).

View Article and Find Full Text PDF

RNA binding protein CUGBP2/ETR-3 regulates STAT3 alternative splicing.

Biochem Biophys Res Commun

December 2024

Laboratory of Molecular Medicinal Science, Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan. Electronic address:

Signal transducer and activator of transcription 3 (STAT3) is a multifactorial regulator involved in many biological responses. Alternative splicing of STAT3 pre-mRNA leads to an internal 50-nucleotide deletion of exon 23 selecting an alternative 3' acceptor site, resulting in the generation of two splicing isoforms, STAT3α and STAT3β. STAT3β lacks 55 amino acid-residue transactivation domain at the C-terminal of STAT3α replacing seven unique amino acids.

View Article and Find Full Text PDF

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma.

Cell Death Differ

October 2024

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

Oxaliplatin-based therapeutics is a widely used treatment approach for hepatocellular carcinoma (HCC) patients; however, drug resistance poses a significant clinical challenge. Epigenetic modifications have been implicated in the development of drug resistance. In our study, employing siRNA library screening, we identified that silencing the mA writer METTL3 significantly enhanced the sensitivity to oxaliplatin in both in vivo and in vitro HCC models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!